Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly LLY ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Medicare drug plans can now cover Eli Lilly & Co.'s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that's expected to prove a big boost for the drug company.

A bill to lower the price of insulin drugs and supplies for more North Dakotans attracted passionate discussion at a Thursday ...

Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Medicare has announced the expansion of coverage for Eli Lilly’s Zepbound, a breakthrough drug in the treatment of autoimmune ...

Across China’s west, the Communist Party is placing children in boarding schools to assimilate a generation of Tibetans into the national mainstream and mold them into loyal citizens. By Chris ...

As of 6 January at 10:47:00 am AEDT. Market open.